
ATTR Amyloidosis - Pipeline Insight, 2025
Description
DelveInsight’s, “ATTR Amyloidosis - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in ATTR Amyloidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
ATTR Amyloidosis: Overview
Transthyretin amyloidosis, also known as cardiac amyloidosis, amyloidosis ATTR, transthyretin amyloid cardiomyopathy (ATTR-CM), transthyretin cardiac amyloidosis (ATTR-CM), and TTR amyloidosis, is a condition characterized by the deposition of transthyretin protein in tissues, particularly affecting the heart.
Transthyretin (previously known as prealbumin) is a normal circulating protein that functions as a carrier protein for retinol (vitamin A) and thyroxine. It is primarily synthesized by the liver (>95%). Additionally, in small amounts, it is also produced in the choroid plexus and retinal epithelium. Usually, it circulates in a tetrameric form composed of 4 beta-sheet-rich monomers. However, structural changes in the TTR protein can cause it to misfold and lose the tetrameric form, causing it to aggregate and deposit in various tissues. The myocardium and peripheral nerves are the most common sites for the deposition of misfolded TTR protein. The clinical phenotype of ATTR depends on the type and extent of tissue involvement.
The symptoms of hereditary ATTR (hATTR) amyloidosis can vary widely among people with the condition and even within families. Different symptoms may appear at different times for each person. The age that symptoms of hATTR amyloidosis typically appear ranges from the mid-20s to the mid-60s. Because symptoms of hATTR amyloidosis can worsen over time. The somatic nervous system, which is made up of nerves that connect the brain and spinal cord to the skin and muscles, controls sensation and voluntary movements. Nerve damage in the somatic nervous system can lead to a range of symptoms, including loss of voluntary movement of the hands and feet, and loss of sensitivity to temperature.
Tissue biopsy with histopathology and immunohistochemistry has been used to definitively diagnose amyloidosis. Extracardiac tissue biopsies (such as abdominal fat pad aspirate) have varying and unreliable sensitivity. Tissue samples from orthopedic procedures, such as carpal tunnel syndrome surgery, have unclear diagnostic reliability at this time but may be useful.
Current guidelines for the treatment of ATTR amyloidosis encompass several key approaches. Specific therapies are designed to modify the synthesis, production, and aggregation of amyloid fibrils. In addition to these targeted treatments, symptomatic therapy is employed to address the neurological and cardiovascular complications associated with the disease. Comprehensive support for patients is also crucial, alongside genetic counselling for those with familial forms of ATTR amyloidosis. These combined strategies aim to provide a holistic approach to managing the condition effectively.
""ATTR Amyloidosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ATTR Amyloidosis pipeline landscape is provided which includes the disease overview and ATTR Amyloidosis treatment guidelines. The assessment part of the report embraces, in depth ATTR Amyloidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ATTR Amyloidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the ATTR Amyloidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ATTR Amyloidosis Emerging Drugs
Further product details are provided in the report……..
ATTR Amyloidosis: Therapeutic Assessment
This segment of the report provides insights about the different ATTR Amyloidosis drugs segregated based on following parameters that define the scope of the report, such as:
The report provides insights into different therapeutic candidates in Phase III II, I, preclinical and discovery stage. It also analyses ATTR Amyloidosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ATTR Amyloidosis drugs.
ATTR Amyloidosis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
ATTR Amyloidosis: Overview
Transthyretin amyloidosis, also known as cardiac amyloidosis, amyloidosis ATTR, transthyretin amyloid cardiomyopathy (ATTR-CM), transthyretin cardiac amyloidosis (ATTR-CM), and TTR amyloidosis, is a condition characterized by the deposition of transthyretin protein in tissues, particularly affecting the heart.
Transthyretin (previously known as prealbumin) is a normal circulating protein that functions as a carrier protein for retinol (vitamin A) and thyroxine. It is primarily synthesized by the liver (>95%). Additionally, in small amounts, it is also produced in the choroid plexus and retinal epithelium. Usually, it circulates in a tetrameric form composed of 4 beta-sheet-rich monomers. However, structural changes in the TTR protein can cause it to misfold and lose the tetrameric form, causing it to aggregate and deposit in various tissues. The myocardium and peripheral nerves are the most common sites for the deposition of misfolded TTR protein. The clinical phenotype of ATTR depends on the type and extent of tissue involvement.
The symptoms of hereditary ATTR (hATTR) amyloidosis can vary widely among people with the condition and even within families. Different symptoms may appear at different times for each person. The age that symptoms of hATTR amyloidosis typically appear ranges from the mid-20s to the mid-60s. Because symptoms of hATTR amyloidosis can worsen over time. The somatic nervous system, which is made up of nerves that connect the brain and spinal cord to the skin and muscles, controls sensation and voluntary movements. Nerve damage in the somatic nervous system can lead to a range of symptoms, including loss of voluntary movement of the hands and feet, and loss of sensitivity to temperature.
Tissue biopsy with histopathology and immunohistochemistry has been used to definitively diagnose amyloidosis. Extracardiac tissue biopsies (such as abdominal fat pad aspirate) have varying and unreliable sensitivity. Tissue samples from orthopedic procedures, such as carpal tunnel syndrome surgery, have unclear diagnostic reliability at this time but may be useful.
Current guidelines for the treatment of ATTR amyloidosis encompass several key approaches. Specific therapies are designed to modify the synthesis, production, and aggregation of amyloid fibrils. In addition to these targeted treatments, symptomatic therapy is employed to address the neurological and cardiovascular complications associated with the disease. Comprehensive support for patients is also crucial, alongside genetic counselling for those with familial forms of ATTR amyloidosis. These combined strategies aim to provide a holistic approach to managing the condition effectively.
""ATTR Amyloidosis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ATTR Amyloidosis pipeline landscape is provided which includes the disease overview and ATTR Amyloidosis treatment guidelines. The assessment part of the report embraces, in depth ATTR Amyloidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ATTR Amyloidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence ATTR Amyloidosis R&D. The therapies under development are focused on novel approaches to treat/improve ATTR Amyloidosis.
This segment of the ATTR Amyloidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ATTR Amyloidosis Emerging Drugs
- Vutrisiran: Alnylam Pharmaceuticals
- NN-6019: Novo Nordisk
- ALN-TTRsc04: Alnylam Pharmaceuticals
Further product details are provided in the report……..
ATTR Amyloidosis: Therapeutic Assessment
This segment of the report provides insights about the different ATTR Amyloidosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in ATTR Amyloidosis
- There are approx. 10+ key companies which are developing the therapies for ATTR Amyloidosis. The companies which have their ATTR Amyloidosis drug candidates in the most advanced stage, i.e. Phase III include, Alnylam Pharmaceuticals.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
The report provides insights into different therapeutic candidates in Phase III II, I, preclinical and discovery stage. It also analyses ATTR Amyloidosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ATTR Amyloidosis drugs.
ATTR Amyloidosis Report Insights
- ATTR Amyloidosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing ATTR Amyloidosis drugs?
- How many ATTR Amyloidosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ATTR Amyloidosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the ATTR Amyloidosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for ATTR Amyloidosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Alnylam Pharmaceuticals
- Novo Nordisk
- Sirnaomics
- Arbor Bio
- Vutrisiran
- NN-6019
- ALN-TTRsc04
- STP152G
- ABO-102
Table of Contents
60 Pages
- Introduction
- Executive Summary
- ATTR Amyloidosis: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Phase
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- ATTR Amyloidosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Vutrisiran: Alnylam Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- NN-6019: Novo Nordisk
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ALN-TTRsc04: Alnylam Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- ATTR Amyloidosis Key Companies
- ATTR Amyloidosis Key Products
- ATTR Amyloidosis- Unmet Needs
- ATTR Amyloidosis- Market Drivers and Barriers
- ATTR Amyloidosis- Future Perspectives and Conclusion
- ATTR Amyloidosis Analyst Views
- ATTR Amyloidosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.